Tianjin Gudui Biopharmaceutical Technology

Tianjin Gudui Biopharmaceutical Technology is a China-based biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company focuses on leveraging molecular glue and PROTAC (Proteolysis-targeting chimera) technologies to address previously "undruggable" targets in oncology and other serious diseases. Gudui Bio utilizes a proprietary platform to design highly selective degraders with optimized pharmacological properties and improved safety profiles. Founded in 2021, the company is advancing a pipeline of early-stage candidates through pre-clinical development, with a primary focus on solid tumors and hematological malignancies. Headquartered in Tianjin, the firm has secured significant venture capital backing to build a robust drug discovery engine. The company aims to translate cutting-edge protein degradation science into transformative clinical treatments.